Showing 1 - 5 results of 5 for search 'Arlene S. Swern', query time: 0.03s Refine Results
  1. 1
    A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial

    A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care... by Steven D. Gore, Pierre Fenaux, Valeria Santini, John M. Bennett, Lewis R. Silverman, John F. Seymour, Eva Hellström-Lindberg, Arlene S. Swern, Charles. L. Beach, Alan. F. List

    Published 2013-07-01
    Get full text
    Article
  2. 2
    Early progression of disease as a predictor of survival in chronic lymphocytic leukemia

    Early progression of disease as a predictor of survival in chronic lymphocytic leukemia by Inhye E. Ahn, Charles M. Farber, Matthew S. Davids, David L. Grinblatt, Neil E. Kay, Nicole Lamanna, Anthony Mato, Chadi Nabhan, Pavel Kiselev, Arlene S. Swern, E. Dawn Flick, Kristen Sullivan, Jeff P. Sharman, Christopher R. Flowers

    Published 2017-11-01
    Get full text
    Article
  3. 3
    Longitudinal health‐related quality of life in first‐line treated patients with chronic lymphocytic leukemia: Results from the Connect® CLL Registry

    Longitudinal health‐related quality of life in first‐line treated patients with chronic lymphocytic leukemia: Results from the Connect® CLL Registry by Jeff P. Sharman, Kim Cocks, Chadi Nabhan, Nicole Lamanna, Neil E. Kay, David L. Grinblatt, Christopher R. Flowers, Matthew S. Davids, Pavel Kiselev, Arlene S. Swern, Kristen Sullivan, Mecide M. Gharibo, E. Dawn Flick, Andrew Trigg, Anthony Mato

    Published 2020-07-01
    Get full text
    Article
  4. 4
    KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma

    KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma by Sundar Jagannath, Yi Lin, Hartmut Goldschmidt, Donna Reece, Ajay Nooka, Alicia Senin, Paula Rodriguez-Otero, Ray Powles, Kosei Matsue, Nina Shah, Larry D. Anderson, Matthew Streetly, Kimberly Wilson, Hoa Van Le, Arlene S. Swern, Amit Agarwal, David S. Siegel

    Published 2021-06-01
    Get full text
    Article
  5. 5
    Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect® MDS/AML Disease Registry

    Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect® MDS/AML Disease Registry by Daniel A. Pollyea, Tracy I. George, Mehrdad Abedi, Rafael Bejar, Christopher R. Cogle, Kathryn Foucar, Guillermo Garcia‐Manero, David L. Grinblatt, Rami S. Komrokji, Jaroslaw P. Maciejewski, Dennis A. Revicki, Gail J. Roboz, Michael R. Savona, Bart L. Scott, Mikkael A. Sekeres, Michael A. Thompson, Sandra E. Kurtin, Chrystal U. Louis, Melissa Nifenecker, E. Dawn Flick, Arlene S. Swern, Pavel Kiselev, David P. Steensma, Harry P. Erba

    Published 2020-07-01
    Get full text
    Article

Search Tools: